ERT Reaches Milestone in Supporting Successful New Drug Approvals
Industry Leaders Share Expertise through Complimentary White Paper on ePRO Regulatory Inspections
ERT, a global solutions provider for high-quality patient safety and efficacy endpoint data collection, today announced it has reached a significant milestone in capturing important data to support the approval of new medical products. To date, global regulatory agencies have issued over 300 approvals to biopharmaceutical companies that relied on ERT’s cardiac safety, respiratory, or eCOA solutions to capture critical safety and/or efficacy data in their clinical programs.
In order to receive regulatory approval of new medical treatments, biopharmaceutical companies must first demonstrate the product’s safety and efficacy through a series of controlled clinical trials. ERT’s suite of products and services for cardiac safety, respiratory, and eCOA – which include electronic patient reported outcomes (ePRO) – are repeatedly relied upon for capturing these important data.
“It is extremely rewarding to realize that so many biopharmaceutical companies have brought new medical treatments to market using products and services delivered by ERT,” said Jeffrey Litwin, M.D., CEO of ERT. “We are committed to delivering innovative and reliable solutions that meet the needs of our worldwide customers and supporting their efforts to bring life-enhancing and life-saving medical products to patients who need them.”
ERT is sharing its knowledge of supporting regulatory approvals by offering a complimentary white paper entitled “ePRO Regulatory Inspections: Best Practices for Smooth and Successful Outcomes.” This paper reviews ERT’s experiences in supporting and participating in ePRO regulatory inspections by the U.S. FDA, European Medicines Agency (EMA), specifically BfArM (German Federal Institute for Drugs and Medical Devices), and the Japanese Pharmaceutical and Medical Devices Agency (PMDA), and outlines best practices for minimizing risk in preparation for regulatory inspections of ePRO data collection systems. The paper is available for complimentary download at www.ert.com/clinical/resources/white-papers/.
For additional information on ERT’s proven cardiac safety, respiratory, and eCOA products and services, visit www.ert.com/clinical/clinical-endpoints/.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
A Guide to Patient Engagement & Recruitment Solutions
March 18th 2025Clinical trials have become increasingly complex over the past decades, making participant recruitment more challenging than ever. This guide explores common recruitment obstacles and offers strategies to overcome them using a patient engagement and recruitment solution.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Bridging the Gap: How Chiesi Used External Collaboration to Get Closer to Patients
March 18th 2025Chiesi partnered with Citeline to enhance clinical trial awareness and patient engagement through its FREUD initiative by launching a Trial Portfolio Website, activating 150+ sites, and generating 600+ qualified referrals—learn more about how Citeline helped improve study discoverability, streamline recruitment, and strengthen Chiesi’s presence in key therapeutic areas.
Citeline Patient Engagement & Recruitment Solutions
March 18th 2025Watch Citeline’s 15-minute presentation from Clinical Leader’s Patient Engagement & Recruitment Solutions Expo, where VP Matt Holms explores Direct-to-Data (DTD) patient recruitment. This session takes a deep dive into how complex algorithms, tokenized data, and large data assets can optimize enrollment, highlighting the importance of early strategic recruitment planning and breaking down the unique benefits and real-world applications of DTD.
